Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05885555

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

A Phase 2 Study to Evaluate the Efficacy and Safety of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least a Corticosteroid and a Thrombopoietin Receptor Agonist (TPO-RA)

Sponsor: Novartis Pharmaceuticals

Conditions Primary Immune Thrombocytopenia (ITP)

Interventions Ianalumab

Updated 25 times since 2023 Last updated: Jan 27, 2026 Started: Aug 16, 2023 Primary completion: Feb 5, 2025 Completion: Mar 19, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05885555, this PHASE2 trial focuses on Primary Immune Thrombocytopenia (ITP) and remains ongoing. Sponsored by Novartis Pharmaceuticals, it has been updated 25 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

25 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Nov 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 20 earlier versions

Jul 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE2
May 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aydin, Turkey (Türkiye) , Barcelona, Spain , Beijing, China , Boston, United States , CABA, Argentina , Dresden, Germany , Edirne, Turkey (Türkiye) , Garran, Australia , Giessen, Germany , Glasgow, United Kingdom and 13 more locations